2024-11-10 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance Comparison:**

Pfizer Inc. (PFE) has underperformed significantly compared to the S&P 500 (VOO) in the given period. The cumulative return for PFE is -15.14%, while VOO has generated a return of 141.71%. This represents a substantial difference of **-156.85** points, placing PFE at the lowest point in the historical data range.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-------|------|
| 2015-2017 | 15.6% | 17.9% | -14.6% | 0.8 |
| 2016-2018 | 36.6% | 17.9% | 11.9% | 0.7 |
| 2017-2019 | 18.7% | 22.5% | -24.4% | 0.8 |
| 2018-2020 | 6.5% | 32.9% | -32.6% | 0.7 |
| 2019-2021 | 43.9% | 32.9% | -45.9% | 0.6 |
| 2020-2022 | 38.0% | 29.5% | 20.2% | 0.6 |
| 2021-2023 | -21.8% | 49.7% | -50.6% | 0.4 |
| 2022-2024 | -51.5% | 46.1% | -76.2% | 0.5 |

The analysis shows a generally negative Alpha, indicating underperformance relative to the benchmark, and a Beta fluctuating around 0.7-0.8, indicating less volatility than the market. 

**2. Recent Price Movement:**

* **Closing Price:** $27.46 (Last Market: $26.72)
* **5-day Moving Average:** $27.73
* **20-day Moving Average:** $28.62
* **60-day Moving Average:** $28.91

The stock price is below all three moving averages, indicating potential downward pressure and a possible short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 24.12 - Suggests the stock is oversold and could potentially rebound in the short-term.
* **PPO:** -0.5 - Negative PPO indicates a downtrend, although relatively weak.
* **Relative Divergence:** -0.4 - Short-term downward trend in relative performance.
* **Expected Return:** 0.0% - The potential for long-term outperformance (over 2 years) relative to the S&P 500 is limited.

**4. Recent Earnings Performance and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-29 | 1.06 | 0.614 |
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |

The most recent earnings report for the quarter ending October 29th, 2024, showed EPS of $1.06, surpassing the estimated EPS of $0.614. This indicates positive earnings growth and a potential catalyst for a short-term price increase.

**5. Financial Information Analysis:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $17.70B | 70.27% |
| 2024-06-30 | $13.28B | 75.16% |
| 2024-03-31 | $14.88B | 77.29% |
| 2023-12-31 | $14.25B | 46.92% |
| 2023-09-30 | $13.49B | 31.30% |

Pfizer has been showing strong revenue and profit margin growth over the past year, particularly in the most recent quarters. This demonstrates consistent financial health and profitability. 

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $92.29B | 4.84% |
| 2024-06-30 | $87.70B | 0.05% |
| 2024-03-31 | $92.28B | 3.38% |
| 2023-12-31 | $89.01B | -3.78% |
| 2023-09-30 | $96.93B | -2.46% |

ROE has shown improvement in the recent quarters, indicating better returns on shareholder investment.

**6. News and Recent Issues:**

* **Recent Earnings Release:**  Pfizer's recent earnings report was positively received by the market, with the stock price increasing on the news. The report demonstrated strong earnings growth and beat analyst expectations. This news has likely contributed to the recent upward pressure on the stock.
* **Recent Market Outlook:** Despite the recent earnings beat, Pfizer's stock faces challenges due to its high valuation and dependence on its COVID-19 vaccine and treatment products. Future revenue growth might be limited once the pandemic subsides.
* **Analyst Opinions:** Most analysts remain optimistic about Pfizer's long-term prospects, citing its strong research and development pipeline and dominance in the pharmaceutical market.

**7. Comprehensive Analysis:**

Pfizer (PFE) currently faces a challenging situation with its share price significantly lagging behind the market. However, the recent positive earnings report and strong financial performance suggest a potential turnaround. The company's long-term prospects are supported by its strong research and development pipeline and established market position. While near-term volatility is expected, investors considering long-term investments might find PFE a suitable option, considering its potential for growth and resilience in the pharmaceutical industry.

**Important Considerations:**

* **COVID-19 Dependence:** Pfizer's reliance on COVID-19 products poses a risk to future growth, as demand may decline once the pandemic subsides.
* **Valuation:** The stock's high valuation may limit further upward movement.
* **Competition:** Pfizer faces intense competition in the pharmaceutical market, which can impact market share and profitability.

**Disclaimer:** This report is based on publicly available information and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making any investment decisions. 
